PeptiDream Achieves Preclinical Milestone in siRNA Delivery Collaboration with Alnylam
I'm PortAI, I can summarize articles.
PeptiDream Inc. has reached a preclinical milestone in its collaboration with Alnylam Pharmaceuticals, focusing on peptide-siRNA conjugates for RNAi therapeutics. PeptiDream will receive an undisclosed milestone payment and is eligible for further payments and royalties. The collaboration began in 2021, targeting RNAi delivery beyond the liver.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments